Logo Made in Germany BIO 2017

Fraunhofer ITEM takes over and continues development of inhalation technology assets from Takeda

(Hannover, Germany) The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunhofer ITEM. The transfer includes the CPA technology platform – the technology for continuous aerosolization of powdery substances – and the know-how to manufacture recombinant surfactant protein C, together with the associated intellectual property. The Fraunhofer ITEM is thus in a position to continue the development of therapies involving continuous inhalation of surfactant and other medications, begun 10 years ago as contract research on behalf of industry.

Exhibitor: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Your personal organizer

Your personal organizer

Print list  |  Save as PDF
Xell AG
Booth number: